This one-day conference focused on significant developments in FDA and DEA’s regulation of controlled substances. The program brought together government, industry and public interest experts to provide updates on the latest regulations and legislation affecting controlled substances’ stakeholders. Participants discussed key developments after passage of the Food and Drug Administration Safety and Innovation Act (FDASIA); opioid REMS requirements; and important scheduling and re-scheduling cases from the past year. Panelists engaged attendees in interactive dialogue on current hot topics and ongoing legal and policy decisions.
Attendees at our 2012 Controlled Substances Conference included representatives from the following companies:
|Arnold & Porter LLP |
Cadwalader, Wickersham & Taft LLP
Cardinal Health, Inc.
Covington & Burling LLP
Department of Justice
Drug Enforcement Administration
Eli Lilly and Company
Endo Pharmaceuticals Inc.
FDA - CDER
FDA - CVM
FDA - OC
Federal Trade Commission
Healthcare Distribution Management Association
Henry Schein, Inc.
Hogan Lovells LLP
Hyman, Phelps & McNamara, P.C.
Jazz Pharmaceuticals, Inc.
Johnson & Johnson
K&L Gates LLP
|Kleinfeld, Kaplan & Becker, LLP |
Krieg DeVault LLP
Leavitt Partners, LLC
National Association of Chain Drug Stores
North Carolina Board of Pharmacy
Otsuka America Pharmaceutical, Inc.
Parsons Behle & Latimer
Pharma Compliance Group, Inc.
Pharmaceutical Education & Research Institute, Inc. (PERI)
Pinney Associates, Inc.
Prescription Drug Research Center LLC
Purdue Pharma L.P.
Shire Specialty Pharmaceuticals
State University of NY at Buffalo
The Drug & Chemical Advisory Group, LLC
United BioSource Corporation
University of Maryland School of Pharmacy